Technical Analysis for RYTM - Rhythm Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 26.71 -0.56% -0.15
RYTM closed down 0.56 percent on Monday, May 20, 2019, on 1.15 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical RYTM trend table...

Date Alert Name Type % Chg
Bollinger Band Squeeze Range Contraction 0.00%
Upper Bollinger Band Walk Strength 0.00%
BB Squeeze + Upper Band Touch Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Upper Bollinger Band Touch Strength 0.00%
20 DMA Support Bullish -0.56%
Bollinger Band Squeeze Range Contraction -0.56%
Stochastic Reached Overbought Strength -0.56%
BB Squeeze + Upper Band Touch Range Contraction -0.56%
Above Upper BB Strength -0.56%

Older signals for RYTM ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity. Setmelanotide serves as replacement therapy for the treatment of melanocortin-4, or MC4, pathway deficiencies. MC4 pathway deficiencies result in the disruption of satiety signals and energy homeostasis in the body, which, in turn, leads to intense feelings of hunger and to obesity. The Company also focused on obesity related to six single gene-related, or monogenic, MC4 pathway deficiencies pro-opiomelanocortin, or POMC, leptin receptor, or LepR, Bardet-Biedl syndrome, Alstrom syndrome, POMC heterozygous, and POMC epigenetic disorders.
Biopharmaceutical Medical Specialties Organ Systems Obesity Peptide Hormones Peptides Metabolic Disorders
Is RYTM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 37.23
52 Week Low 23.44
Average Volume 87,423
200-Day Moving Average 28.448
50-Day Moving Average 27.3734
20-Day Moving Average 25.764
10-Day Moving Average 25.951
Average True Range 1.1717
ADX 17.36
+DI 16.4486
-DI 14.1238
Chandelier Exit (Long, 3 ATRs ) 23.9949
Chandelier Exit (Short, 3 ATRs ) 27.8351
Upper Bollinger Band 26.8517
Lower Bollinger Band 24.6763
Percent B (%b) 0.93
BandWidth 8.443565
MACD Line -0.1308
MACD Signal Line -0.3988
MACD Histogram 0.268
Fundamentals Value
Market Cap 696.44 Million
Num Shares 26.1 Million
EPS -3.13
Price-to-Earnings (P/E) Ratio -8.53
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 28.03
Resistance 3 (R3) 27.96 27.44 27.81
Resistance 2 (R2) 27.44 27.11 27.48 27.74
Resistance 1 (R1) 27.08 26.90 26.82 27.15 27.66
Pivot Point 26.56 26.56 26.44 26.60 26.56
Support 1 (S1) 26.20 26.23 25.94 26.27 25.76
Support 2 (S2) 25.68 26.02 25.72 25.68
Support 3 (S3) 25.32 25.68 25.61
Support 4 (S4) 25.39